| Drook Medical Center | |
|
308 N Jefferson Street Converse IN 46919 | |
| (765) 395-5091 | |
| (765) 395-5128 |
| Full Name | Drook Medical Center |
|---|---|
| Speciality | Family Medicine |
| Location | 308 N Jefferson Street, Converse, Indiana |
| Authorized Official Name and Position | Paul L Usher (PRESIDENT/CEO) |
| Authorized Official Contact | 7656624776 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Drook Medical Center 1251 W Kem Rd Suite E Marion IN 46952-2555 Ph: (765) 662-4133 | Drook Medical Center 308 N Jefferson Street Converse IN 46919 Ph: (765) 395-5091 |
| NPI Number | 1548313844 |
|---|---|
| Provider Enumeration Date | 01/19/2007 |
| Last Update Date | 02/19/2009 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548313844 | NPI | - | NPPES |
| 100269250 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
News Archive
Pfizer Inc. announced today that the European Medicines Agency has accepted Pfizer's filing for regulatory review of axitinib for patients with advanced renal cell carcinoma after failure of prior systemic treatment.
To identify new potential therapeutic targets for SARS-CoV-2, a team of scientists at the New York Genome Center, New York University, and the Icahn School of Medicine at Mount Sinai, performed a genome-scale, loss-of-function CRISPR screen to systematically knockout all genes in the human genome.
The U.S. Senate's failure to act before this week's 21 percent Medicare physician payment cut has put seniors' health care at grave risk. A new American Medical Association (AMA) physician survey shows that many physicians are already limiting the number of Medicare patients they treat. The AMA today launched a multi-million dollar national advertising campaign, with ads on TV and radio and in newspapers, including The New York Times, USAToday and The Wall Street Journal.
Though the FDA's Monday approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at risk of contracting the virus "was hailed by many as an important step in the fight against AIDS, concerns that people will incorrectly use the drug - potentially spurring drug resistance - led others to blast the agency for not laying down tougher rules," the Wall Street Journal's "Health Blog" writes.
› Verified 8 days ago